Navigation Links
Pfenex Inc. Announces Pricing Of Initial Public Offering
Date:7/23/2014

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) today announced the pricing of its initial public offering of 8,333,333 shares of its common stock at a price to the public of $6.00 per share. In addition, Pfenex has granted the underwriters a 30-day option to purchase up to 1,250,000 additional shares of common stock at the initial public offering price. The shares are expected to begin trading on the NYSE MKT on July 24, 2014, under the symbol "PFNX".

William Blair & Company, L.L.C. and JMP Securities LLC are acting as joint book-running managers for the offering and Mizuho Securities USA Inc. is acting as a co-manager.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 222 West Adams Street, Chicago, IL 60606, or by calling (800) 621-0687 or by emailing a request to prospectus@williamblair.com; or from JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, or by calling (415) 835-8985.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology™ platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.  

Logo - http://photos.prnewswire.com/prnh/20140715/127348


'/>"/>
SOURCE Pfenex Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
2. Elsevier announces the launch of open access journal: Bone Reports
3. Elsevier announces launch of new journal: Current Opinion in Insect Science
4. SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT
5. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
6. BrightFocus Foundation announces 55 new grantees in Alzheimers and vision research
7. Elsevier Announces the launch of open access journal: New Negatives in Plant Science
8. Institute of Physics announces 2014 award winners
9. Elsevier announces the launch of a new journal: Current Opinion in Behavioral Sciences
10. Autism speaks announces Meixner Postdoctoral Fellowships in translational research
11. Ecological Society of America announces 2014 Fellows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2019)... ARLINGTON, Va. (PRWEB) , ... February 19, 2019 ... ... today announced the appointment of Mark Hozza as Chief Commercial Officer of the ... Mark is responsible for the performance, strategy, and alignment of all market research ...
(Date:2/13/2019)... ... February 13, 2019 , ... Carstens, Inc. is ... features Wi-Fi enabled RFID Locks that provide healthcare facilities with instant control of ... on the network for superior access control and shrinkage protection. For years WALLAroo cabinets ...
(Date:2/11/2019)... ... February 11, 2019 , ... Allotrope Foundation ... the phased release of the Allotrope™ Framework for standardizing scientific data and its ... released Allotrope™ Data Format (ADF) and application programming interfaces (APIs), and the Allotrope ...
Breaking Biology News(10 mins):
(Date:1/30/2019)... ... January 30, 2019 , ... The Society for Laboratory Automation ... discuss best practices for laboratory automation and screening. This year the conference will ... conference, Visikol will be at booth #345 and throughout the conference will highlight ...
(Date:1/24/2019)... , ... January 22, 2019 , ... Dr. Douglas Stramel ... Pall Veterinary Platelet Enhancement Therapy System (V-PET™) for nearly three years. ... Regenerative Cell Therapy since 2007 and began using V-PET™ 2016. V-PET™ is ...
(Date:1/20/2019)... ... January 17, 2019 , ... ... recently, the exclusive purview of physicians. That's changing as many services now exist ... consumer (DTC) laboratory testing market totaled $208 million in 2018, according to Kalorama ...
(Date:1/15/2019)... ... ... Congress designating January as Cervical Health Awareness Month , myLAB Box , ... the risk of Cervical Cancer. , Cervical cancer is a slow-growing cancer that ... STD and an STI that almost half of all American adults have. While there ...
Breaking Biology Technology: